0.2720
-0.0180
(-6.21%)
At close: 4:04:48 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
50,480
50,480
44,176
40,656
52,826
Operating Income
-50,480
-50,480
-44,176
-40,656
-52,826
Net Non Operating Interest Income Expense
229
229
122
-2
-1,859
Pretax Income
-50,252
-50,252
-44,054
-40,726
-52,142
Net Income Common Stockholders
-50,252
-50,252
-44,054
-40,726
-52,142
Diluted NI Available to Com Stockholders
-50,252
-50,252
-44,054
-40,726
-52,142
Basic EPS
-0.11
-0.11
-0.24
-0.26
-0.36
Diluted EPS
-0.11
-0.11
-0.24
-0.26
-0.36
Basic Average Shares
452,172.5090
452,172.5090
178,612.7750
156,359.0690
144,747.0730
Diluted Average Shares
532,978.7110
452,172.5090
178,612.7750
156,359.0690
144,747.0730
Total Operating Income as Reported
-50,480
-50,480
-44,176
-40,724
-51,233
Total Expenses
50,480
50,480
44,176
40,656
52,826
Net Income from Continuing & Discontinued Operation
-50,252
-50,252
-44,054
-40,726
-52,142
Normalized Income
-50,252
-50,252
-44,054
-40,726
-52,142
Interest Income
229
229
122
--
--
Interest Expense
--
--
--
2
1,859
Net Interest Income
229
229
122
-2
-1,859
EBIT
-50,480
-50,480
-44,176
-40,724
-50,283
EBITDA
-50,480
-50,480
-44,176
-40,724
-50,283
Net Income from Continuing Operation Net Minority Interest
-50,252
-50,252
-44,054
-40,726
-52,142
Normalized EBITDA
-50,480
-50,480
-44,176
-40,724
-50,283
12/31/2021 - 4/19/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RPD.MU Royalty Pharma plc
28.20
-3.09%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
2GH.BE Merus NV
36.80
+6.36%
P0F.F Egetis Therapeutics AB (publ)
0.3270
+2.35%
B9A.F BioArctic AB (publ)
14.71
-0.94%
7PO.F Poxel S.A.
0.5300
0.00%
HQ1.MU Oruka Therapeutics Inc. R
6.40
0.00%
2HA.F Spero Therapeutics, Inc.
0.4965
-7.20%
BT3.BE Lineage Cell Therapeutics Inc
0.3580
-2.72%
05Y.F Vivoryon Therapeutics N.V.
1.8040
-1.64%